文献速递前列腺癌

多参数磁共振与经直肠引导前列腺穿刺结果不一致的处理:经会阴靶向穿刺的关键作用

Managing Discordant Findings Between Multiparametric Magnetic Resonance Imaging and Transrectal Magnetic Resonance Imaging-directed Prostate Biopsy-The Key Role of Magnetic Resonance Imaging-directed Transperineal Biopsy.
PubMed 文献 · Eur Urol Oncol · 2021-06-19

该研究回顾了558例因疑似或治疗局限性前列腺癌转诊的病例,其中132例(23.7%)在多参数磁共振(mpMRI)与经直肠超声引导穿刺(TRUS-P)之间存在结果不一致。102例接受经会阴索引病灶靶向穿刺(TPER-IT)再评估,结果显示TPER-IT以更少的穿刺针数获得更多肿瘤组织,并使40%随访患者和49%主动监测患者治疗建议改为手术或调强放疗。结论推荐对I-II型不一致患者行多学科评估及TPER-IT再评估。

要点

  • mpMRI与TRUS-P结果不一致见于23.7%(132/558)的患者。
  • TPER-IT以更少针数(7 vs 14)获得更多肿瘤组织(56 vs 42.5 mm)。
  • 再评估后40%随访和49%主动监测患者改为手术或放疗。

核心结论

  • TRUS-P后病理与影像不一致比例显著,TPER-IT能更好判断肿瘤存在及分级并影响治疗推荐。
  • 推荐对I-II型不一致行mpMRI与TRUS-P多学科回顾及TPER-IT再评估。

研究设计与样本

  • 回顾性多学科评估558例疑似或治疗局限性前列腺癌病例,132例(23.7%)存在TRUS-P后不一致,其中102例接受TPER-IT再评估。
  • 不一致分三型:I型为PI-RADS≥4索引病灶穿刺阴性或ISUP 1级;II型为前部索引病灶穿刺阴性或ISUP 1级;III型为PI-RADS≥3索引病灶癌组织<3 mm。

主要发现

  • TPER-IT穿刺针数少于初始TRUS-P(7 vs 14,p<0.0001),但获得癌组织长度更多(56 vs 42.5 mm,p=0.0003)。
  • 初始考虑随访的30例中12例(40%)及考虑主动监测的61例中30例(49%)在TPER-IT后改为手术或调强放疗。

关键数值与推荐

  • I型不一致定义:PI-RADS≥4索引病灶穿刺阴性或ISUP 1级癌。
  • II型不一致定义:前部索引病灶穿刺阴性或ISUP 1级癌。
  • III型不一致定义:PI-RADS≥3索引病灶癌组织<3 mm。

临床怎么用

  • 对mpMRI与TRUS-P结果不一致(尤其I-II型)患者,建议多学科回顾影像与病理后行TPER-IT再评估。
  • 再评估可能改变风险分层及治疗推荐,避免对侵袭性癌的低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Discordant findings between multiparametric magnetic resonance imaging (mpMRI) and transrectal image-guided biopsies of the prostate (TRUS-P) may result in inadequate risk stratification of localized prostate cancer. OBJECTIVE: To assess transperineal image-guided biopsies of the index target (TPER-IT) in terms of disease reclassification and treatment recommendations. DESIGN, SETTING, AND PARTICIPANTS: Cases referred for suspicion or treatment of localized prostate cancer were reviewed in a multidisciplinary setting, and discordance was characterized into three scenarios: type I-negative biopsies or International Society of Urological Pathology (ISUP) grade 1 cancer in Prostate Imaging Reporting and Data System (PI-RADS) ≥4 index target (IT); type II-negative biopsies or ISUP grade 1 cancer in anterior IT; and type III-<3 mm stretch of cancer in PI-RADS ≥3 IT. Discordant findings were characterized in 132/558 (23.7%) patients after TRUS-P. Of these patients, 102 received reassessment TPER-IT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary objective was to report changes in treatment recommendations after TPER-IT. Therefore, cores obtained by primary TRUS-P and TPER-IT were analyzed in terms of cancer detection, ISUP grade, and Cambridge Prognostic Group classification using descriptive statistics. RESULTS AND LIMITATIONS: TPER-IT biopsies that consisted of fewer cores than the initial TRUS-P (seven vs 14, p < 0.0001) resulted in more cancer tissue materials for analysis (56 vs 42.5 mm, p = 0.0003). As a result, 40% of patients initially considered for follow-up (12/30) and 49% for active surveillance (30/61) were reassigned after TPER-IT to surgery or intensity-modulated radiotherapy. CONCLUSIONS: Nonconcordance between pathology and imaging was observed in a significant proportion of patients receiving TRUS-P. TPER-IT better informed the presence and grade of cancer, resulting in a significant impact on treatment recommendations. A multidisciplinary review of mpMRI and TRUS-P findings and reassessment TPER-IT in type I-II discordances is recommended. PATIENT SUMMARY: In this report, patients with suspicious imaging of the prostate, but no or well-differentiated cancer on transrectal image-guided -biopsies, were offered transperineal image-guided biopsies for reassessment. We found that a large share of these had a more aggressive cancer than initially suspected. We conclude that discordant results warrant reassessment transperineal image-guided biopsies as these may impact disease risk classification and treatment recommendations.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bajeot AS, Covin B, Meyrignac O, et al. Managing Discordant Findings Between Multiparametric Magnetic Resonance Imaging and Transrectal Magnetic Resonance Imaging-directed Prostate Biopsy-The Key Role of Magnetic Resonance Imaging-directed Transperineal Biopsy. Eur Urol Oncol. 2021. PMID: 34154979. doi:10.1016/j.euo.2021.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。